Be Biopharma, a Cambridge, MA-based developer of Engineered B Cell Medicines (BeCM), closed a $130m financing.
The spherical, which introduced whole funding to over $180m, was led by ARCH Enterprise Companions with participation from Bristol Myers Squibb and different new traders, alongside current traders together with Atlas Enterprise, RA Capital Administration, Alta Companions, Longwood Fund and Takeda Ventures. Steven Gillis, Ph.D., Managing Director at ARCH Enterprise Companions, joined the Board of Administrators. Robert Nelsen, co-founder and Managing Director of ARCH Enterprise Companions and Robert Plenge, M.D., Ph.D., Senior Vice President, and Head of the Immunology, Cardiovascular and Fibrosis Thematic Analysis Middle at Bristol Myers Squibb, joined as observers.
The corporate intends to make use of the funds to advance its proprietary autologous and allogeneic BeCM platforms throughout a number of therapeutic areas and progress pipeline candidates towards the clinic.
Based in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Youngsters’s Analysis Institute and led by Joanne Smith-Farrell, Ph.D., Chief Govt Officer, Be Biopharma is advancing Engineered B Cell Medicines (BeCM) to enhance sufferers’ lives who’re residing with most cancers, uncommon illnesses and different severe circumstances. The corporate has a broad pipeline initially targeted on uncommon illness and most cancers. As they advance its platform, Be Biopharma plans to broaden into further therapeutic areas together with infectious illness, neurological circumstances and autoimmune illness.